Ron Gilissen

2.6k total citations
40 papers, 1.4k citations indexed

About

Ron Gilissen is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Ron Gilissen has authored 40 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 11 papers in Pharmacology and 10 papers in Oncology. Recurrent topics in Ron Gilissen's work include Pharmacogenetics and Drug Metabolism (11 papers), Drug Transport and Resistance Mechanisms (8 papers) and Analytical Chemistry and Chromatography (5 papers). Ron Gilissen is often cited by papers focused on Pharmacogenetics and Drug Metabolism (11 papers), Drug Transport and Resistance Mechanisms (8 papers) and Analytical Chemistry and Chromatography (5 papers). Ron Gilissen collaborates with scholars based in Belgium, United States and Netherlands. Ron Gilissen's co-authors include Claire Mackie, Vikash K. Sinha, Marjoleen Nijsen, Stefan S. De Buck, Luca A. Fenu, Michael W.H. Coughtrie, Andreas Smolders, Jeroen Luyten, Jean‐Pierre Erauw and Anthony A. Fryer and has published in prestigious journals such as Cancer Research, Biochemical Journal and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Ron Gilissen

39 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ron Gilissen Belgium	17	566	498	348	153	126	40	1.4k
Raf Mols Belgium	28	132 0.2×	712 1.4×	559 1.6×	244 1.6×	272 2.2×	53	2.8k
Jianghong Fan United States	20	307 0.5×	423 0.8×	357 1.0×	102 0.7×	92 0.7×	45	1.5k
Keith Hoffmaster United States	16	409 0.7×	298 0.6×	625 1.8×	79 0.5×	154 1.2×	20	1.4k
Wenjuan Zhang China	18	158 0.3×	757 1.5×	85 0.2×	17 0.1×	26 0.2×	45	1.3k
Jonathan Cheong United States	13	177 0.3×	444 0.9×	412 1.2×	92 0.6×	161 1.3×	30	1.3k
James Grogan United States	16	622 1.1×	462 0.9×	464 1.3×	162 1.1×	28 0.2×	30	1.6k
Alison J. Foster United Kingdom	16	418 0.7×	230 0.5×	160 0.5×	23 0.2×	33 0.3×	23	1.1k
Inge A.M. de Graaf Netherlands	24	405 0.7×	416 0.8×	651 1.9×	57 0.4×	60 0.5×	57	1.9k
Mohamed W. Attwa Saudi Arabia	27	214 0.4×	907 1.8×	498 1.4×	177 1.2×	46 0.4×	141	1.7k
Yitian Zhou Sweden	25	900 1.6×	562 1.1×	353 1.0×	26 0.2×	127 1.0×	71	2.0k

Countries citing papers authored by Ron Gilissen

Since Specialization

Citations

This map shows the geographic impact of Ron Gilissen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Gilissen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Gilissen more than expected).

Fields of papers citing papers by Ron Gilissen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron Gilissen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Gilissen. The network helps show where Ron Gilissen may publish in the future.

Co-authorship network of co-authors of Ron Gilissen

This figure shows the co-authorship network connecting the top 25 collaborators of Ron Gilissen. A scholar is included among the top collaborators of Ron Gilissen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron Gilissen. Ron Gilissen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Versele, Matthias, Burkhard Haefner, Berthold Wroblowski, et al.. (2016). Abstract 4800: Covalent Flt3-Cys828 inhibition represents a novel therapeutic approach for the treatment of Flt3-ITD and Flt3-D835 mutant acute myeloid leukemia. Cancer Research. 76(14_Supplement). 4800–4800. 2 indexed citations

Sinha, Vikash K., Stefan S. De Buck, Luca A. Fenu, et al.. (2011). Towards a Better Prediction of Peak Concentration, Volume of Distribution and Half-Life after Oral Drug Administration in Man, Using Allometry. Clinical Pharmacokinetics. 50(5). 307–318. 15 indexed citations

Bergh, An Van den, Vikash Sinha, Ron Gilissen, et al.. (2011). Prediction of Human Oral Plasma Concentration-Time Profiles Using Preclinical Data. Clinical Pharmacokinetics. 50(8). 505–517. 23 indexed citations

Fenu, Luca A., Ard Teisman, Stefan S. De Buck, et al.. (2009). Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay. Journal of Computer-Aided Molecular Design. 23(12). 883–895. 4 indexed citations

Buntinx, Mieke, Bart Hermans, Dieder Moechars, et al.. (2008). Pharmacological Profile of JNJ-27141491 [(S)-3-[3,4-Difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1 H-imidazole-4-carboxyl Acid Methyl Ester], as a Noncompetitive and Orally Active Antagonist of the Human Chemokine Receptor CCR2. Journal of Pharmacology and Experimental Therapeutics. 327(1). 1–9. 22 indexed citations

Sinha, Vikash K., Stefan S. De Buck, Luca A. Fenu, et al.. (2008). Predicting Oral Clearance in Humans. Clinical Pharmacokinetics. 47(1). 35–45. 37 indexed citations

Saenen, Johan, R. J. E. Jongbloed, Carlo Marcelis, et al.. (2007). A single hERG mutation underlying a spectrum of acquired and congenital long QT syndrome phenotypes. Journal of Molecular and Cellular Cardiology. 43(1). 63–72. 14 indexed citations

Buck, Stefan S. De, Vikash K. Sinha, Luca A. Fenu, et al.. (2007). The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools. Drug Metabolism and Disposition. 35(4). 649–659. 75 indexed citations

Buck, Stefan S. De, Vikash K. Sinha, Luca A. Fenu, et al.. (2007). Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs. Drug Metabolism and Disposition. 35(10). 1766–1780. 192 indexed citations

10.

Ethirajulu, Kantharaj, et al.. (2005). Simultaneous measurement of metabolic stability and metabolite identification of 7‐methoxymethylthiazolo[3,2‐a]pyrimidin‐5‐one derivatives in human liver microsomes using liquid chromatography/ion‐trap mass spectrometry. Rapid Communications in Mass Spectrometry. 19(8). 1069–1074. 7 indexed citations

11.

Ethirajulu, Kantharaj, et al.. (2003). Simultaneous measurement of drug metabolic stability and identification of metabolites using ion‐trap mass spectrometry. Rapid Communications in Mass Spectrometry. 17(23). 2661–2668. 38 indexed citations

12.

Roymans, Dirk, Angelique M. Leone, J. Brandon Parker, et al.. (2003). Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochemical Pharmacology. 67(3). 427–437. 57 indexed citations

13.

Leathart, Julian, Elaine Mutch, Stuart Dunn, et al.. (2002). CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochemical Pharmacology. 64(11). 1579–1589. 197 indexed citations

14.

Gilissen, Ron, et al.. (2000). Human hepatic metabolism of a novel 2-carboxyindole glycine antagonist for stroke: invitro-in vivocorrelations. Xenobiotica. 30(9). 843–856. 5 indexed citations

15.

Gilissen, Ron, et al.. (2000). Identification of UDP-Glucuronosyltransferases Involved in the Human Hepatic Metabolism of GV150526, a Novel Glycine Antagonist. Drug metabolism and drug interactions. 16(3). 173–190. 3 indexed citations

16.

Meerman, John H.N., et al.. (1994). Sulfation of carcinogenic aromatic hydroxylamines and hydroxamic acids by rat and human sulfotransferases: substrate specificity, developmental aspects and sex differences. Chemico-Biological Interactions. 92(1-3). 321–328. 17 indexed citations

17.

Gilissen, Ron, Robert Hume, John H.N. Meerman, & Michael W.H. Coughtrie. (1994). Sulphation of N-hydroxy-4-aminobiphenyl and N-hydroxy-4-acetylaminobiphenyl by human foetal and neonatal sulphotransferase. Biochemical Pharmacology. 48(4). 837–840. 16 indexed citations

18.

Gilissen, Ron & John H.N. Meerman. (1992). Bioactivation of the hepatocarcinogen N-hydroxy-2-acetylaminofluorene by sulfation in the rat liver changes during the cell cycle. Life Sciences. 51(16). 1255–1260. 7 indexed citations

19.

Gilissen, Ron, et al.. (1992). Sulfation of hydroxylamines and hydroxamic acids in liver cytosol from male and female rats and purified aryl sulfotransferase IV. Carcinogenesis. 13(10). 1699–1703. 13 indexed citations

20.

Gilissen, Ron, John H.N. Meerman, & Gerard J. Mulder. (1992). Immobilization of solubilized UDP-glucuronosyltransferase from rat liver microsomes to Sepharose 4B. Biochemical Pharmacology. 43(12). 2661–2663. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact